{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:13:24Z","timestamp":1772741604489,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.clinthera.2013.02.008","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T02:02:02Z","timestamp":1363312922000},"page":"321-332","source":"Crossref","is-referenced-by-count":10,"title":["Budget Impact Modeling for a Single-Tablet Formulation of Ibuprofen and Famotidine for Prevention of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis and\/or Rheumatoid Arthritis"],"prefix":"10.1016","volume":"35","author":[{"given":"Renee","family":"Kuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Peura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.02.008_bib1","series-title":"Wolters Kluwer prescription database","year":"2009"},{"key":"10.1016\/j.clinthera.2013.02.008_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.02.008_bib3","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1097\/00005344-200605001-00011","article-title":"GI risk and risk factors of NSAIDs","volume":"47","author":"Laine","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.02.008_bib4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00042737-200012061-00004","article-title":"Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?","volume":"12","author":"Goldstein","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ajg.2009.115","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0002-9343(89)90344-6","article-title":"Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage","volume":"86","author":"Schoen","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF02063956","article-title":"Effects of nonsteroidal antiinflammatory drugs on ulcerogenesis and gastric secretion in pylorus-ligated rat","volume":"40","author":"Wagner","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2013.02.008_bib8","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.02.008_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 Update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.02.008_bib10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.cgh.2006.08.016","article-title":"Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications","volume":"4","author":"Goldstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2036.2009.04090.x","article-title":"Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines","volume":"30","author":"Laine","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2474-7-79","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice","volume":"7","author":"Moore","year":"2006","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2013.02.008_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01795.x","article-title":"Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs","volume":"18","author":"Sturkenboom","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2007.03358.x","article-title":"Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage","volume":"26","author":"van Soest","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2013.02.008_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.02.008_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib19","series-title":"Vimovo (naproxen and esomeprazole magnesium) [prescribing information]","year":"2011"},{"key":"10.1016\/j.clinthera.2013.02.008_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","article-title":"Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial","volume":"127","author":"Laine","year":"2004","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.clinthera.2013.02.008_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002296","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2013.02.008_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2013.02.008_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1370\/afm.1243","article-title":"Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies","volume":"9","author":"Eom","year":"2011","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","article-title":"Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies","volume":"124","author":"Yu","year":"2011","journal-title":"Am J Med"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2013.02.008_bib28","first-page":"S391","article-title":"Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials","volume":"62","author":"Weinblatt","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.02.008_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3121\/cmr.2007.698","article-title":"An evidence-based update on nonsteroidal anti-inflammatory drugs","volume":"5","author":"Ong","year":"2007","journal-title":"Clin Med Res"},{"key":"10.1016\/j.clinthera.2013.02.008_bib30","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/gast.1997.v112.pm9178671","article-title":"Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration","volume":"112","author":"Hudson","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.02.008_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","article-title":"Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs","volume":"334","author":"Taha","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib32","doi-asserted-by":"crossref","first-page":"A612","DOI":"10.1016\/S0016-5085(09)62818-3","article-title":"Famotidine (FAM) administered orally three times daily produces better gastric acid suppression and control than does twice daily (BID) administration of the same total daily dose","volume":"136","author":"Tidmarsh","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.02.008_bib33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1525-1497.2000.03459.x","article-title":"Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease","volume":"15","author":"Ko","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/kei241","article-title":"Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?","volume":"45","author":"Elliott","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2013.02.008_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00042737-200201000-00010","article-title":"One-year prognosis of primary care dyspepsia: predictive value of symptom pattern, Helicobacter pylori and GP management","volume":"14","author":"Quartero","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib36","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1572-0241.2005.00225.x","article-title":"Guidelines for the management of dyspepsia","volume":"100","author":"Talley","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib37","first-page":"2218","article-title":"Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs","volume":"32","author":"Wilcox","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib38","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2036.2002.01306.x","article-title":"Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis","volume":"16","author":"Ladabaum","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4","article-title":"The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs","volume":"41","author":"Maetzel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2013.02.008_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/egh.11.88","article-title":"HZT-501 (DUEXIS(\u00ae); ibuprofen 800 mg\/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis","volume":"6","author":"Schiff","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib41","series-title":"DUEXIS [prescribing information]","year":"2011"},{"key":"10.1016\/j.clinthera.2013.02.008_bib42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","article-title":"Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs","volume":"12","author":"Garcia Rodriguez","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.clinthera.2013.02.008_bib43","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","article-title":"Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding","volume":"343","author":"Lanas","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.gastro.2011.03.049","article-title":"Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy","volume":"141","author":"Lin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.02.008_bib46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2007.06.058","article-title":"Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs","volume":"133","author":"Ray","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.02.008_bib47","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications","volume":"56","author":"Singh","year":"1999","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.clinthera.2013.02.008_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200629020-00002","article-title":"NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options","volume":"29","author":"Naesdal","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2013.02.008_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3111\/13696990903526676","article-title":"The economics of upper gastrointestinal bleeding in a US managed-care setting: a retrospective, claims-based analysis","volume":"13","author":"Cryer","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2013.02.008_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-9-38","article-title":"Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis","volume":"9","author":"Lanas","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ajg.2010.436","article-title":"Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial","volume":"106","author":"Cryer","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10620-005-1281-1","article-title":"Endoscopy in asymptomatic minidose aspirin consumers","volume":"50","author":"Niv","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2013.02.008_bib53","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1365-2036.2006.02912.x","article-title":"The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor","volume":"23","author":"Goldstein","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.02.008_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7015-4-22","article-title":"Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications","volume":"4","author":"Hernandez-Diaz","year":"2006","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib56","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1093\/eurheartj\/ehp256","article-title":"Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial","volume":"30","author":"Moukarbel","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.02.008_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/qjmed\/hcq169","article-title":"Prevalence and independent factors for gastroduodenal ulcers\/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study","volume":"104","author":"Tamura","year":"2011","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2013.02.008_bib58","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin","volume":"95","author":"Sorensen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.02.008_bib59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.02.008_bib60","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archinte.167.6.540","article-title":"Interventions to enhance medication adherence in chronic medical conditions: a systematic review","volume":"167","author":"Kripalani","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2013.02.008_bib61","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1001\/jama.288.22.2868","article-title":"Interventions to enhance patient adherence to medication prescriptions: scientific review","volume":"288","author":"McDonald","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.02.008_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6963-7-55","article-title":"Patient adherence to medical treatment: a review of reviews","volume":"7","author":"van Dulmen","year":"2007","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2013.02.008_bib63","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gut.2011.239848","article-title":"Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases","volume":"60","author":"van Sosest","year":"2011","journal-title":"Gut"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T22:52:32Z","timestamp":1539816752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0149291813000647"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.02.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}